Skinbiotherap. Share News (SBTX)

SkinBioTherapeutics pleased with progress on two fronts

(Sharecast News) - Skin health-focussed life science company SkinBioTherapeutics said in an update on Wednesday that its partner Sederma, a division of Croda International, was planning to undertake additional studies on SkinBiotix.

SkinBioTherapeutics says Sederma to undertake more SkinBiotix studies

(Alliance News) - SkinBioTherapeutics PLC on Wednesday said that a partner has plans to undertake additional studies on SkinBiotix, which could enhance its commercial potential.

IN BRIEF: SkinBioTherapeutics shares plunge on widened interim loss

SkinBioTherapeutics PLC - skin health-focused life sciences firm - Says interim revenue jumps to GBP76,985 in the six months to December 31, from GBP21,949 a year before. Pretax loss widens to GBP1.4 million from GBP1.2 million, as operational costs climb to GBP918,103 from GBP764,750. In 2023, says focus is on reaching commercial traction with Croda, launching AxisBiotix-Ps into Europe, developing an acne product, among others targets.

AIM WINNERS & LOSERS: Unbound soars on potential takeover offer

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

SkinBioTherapeutics receives Spanish health approval for AxisBioTix-Ps

(Alliance News) - SkinBioTherapeutics PLC on Tuesday said it received Spanish health authority authorisation for AxisBioTix-Ps, its food supplement to treat symptoms associated with psoriasis.

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

UPDATE: SkinBioTherapeutics raises GBP2.6 million; annual loss widens

(Alliance News) - SkinBioTherapeutics PLC on Wednesday said it raised GBP2.6 million in total through its share placing and retail offer.

SkinBioTherapeutics raises GBP2.6 million from placing, retail offer

(Alliance News) - SkinBioTherapeutics PLC on Wednesday said it raised GBP2.6 million in total through its share placing and retail offer.

TRADING UPDATES: Dev Clever to cancel shares; Tintra raises funds

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

SkinBioTherapeutics shares fall as probiotic AxisBiotix-PS sales drop

(Alliance News) - SkinBioTherapeutics PLC on Wednesday said the sales of its psoriasis food supplement AxisBiotix-PS were lower than expected and said it found a form of bacteria that prevents gum disease.

OptiBiotix shares plunge on "very difficult trading" in half-year

(Alliance News) - OptiBiotix Health PLC on Wednesday lamented a strenuous half-year but eyed growing sales and business, seeing itself in a strong position.

IN BRIEF: OptiBiotix Health annual profit up; confident in prospects

OptiBiotix Health PLC - York-based probiotics developer tackling cardiovascular diseases and lifestyle conditions - Reports higher profit and revenue in 2021 as probiotic business sells more. Pretax profit rises to GBP6.2 million from GBP5.7 million in 2020. Revenue from contracts with customers grows 45% to GBP2.2 million from GBP1.5 million.

IN BRIEF: SkinBioTherapeutics unaware of reason for share price drop

SkinBioTherapeutics PLC- Skin health-focused life sciences company - Says it is not aware of any "material commercial or operational" reason for the fall in its share price on Monday. Adds that it continues to focus on driving sales of its AxisBiotix-Ps probiotic food supplement, which holds a subscriber-retention rate of more than 80%.

IN BRIEF: SkinBioTherapeutics loss widens as underperforms in US

SkinBioTherapeutics PLC- Skin health-focused life sciences company - Says pretax loss widens to GBP1.2 million in six months to December 31, from GBP628,241 a year earlier. US market penetration with its only product launched in October 2021, AxisBiotix-Ps, for treating Psoriasis, was slower than expected, company adds. Revenue for the half comes in at GBP21,949, against none a year earlier. For the financial year ending in June, the company expects revenue materially below expectations, it warns.